NACDS RxImpact calls on Senate to support action on DIR fees

NACDS RxImpact pharmacy advocates are calling on Senators to sign a letter to HHS Secretary Alex Azar illustrating the negative effects on Medicare patients and on pharmacies of the rapid expansion of the use of direct and indirect remuneration (DIR) fees in recent years. Sens. Shelley Moore Capito (R-WV) and Jon Tester (D-MT) wrote the letter.

NACDS RxImpact pharmacy advocates are calling on Senators to sign a letter to HHS Secretary Alex Azar illustrating the negative effects on Medicare patients and on pharmacies of the rapid expansion of the use of direct and indirect remuneration (DIR) fees in recent years. Sens. Shelley Moore Capito (R-WV) and Jon Tester (D-MT) wrote the letter. "NACDS thanks Sen. Shelley Moore Capito and Sen. Jon Tester — as well as all of the senators who are signing the letter — for their leadership in explaining the consequences of the current state of DIR fees, and for urging Secretary Azar to not allow the current focus on drug prices to pass without taking meaningful action on this extremely critical issue," said NACDS president and CEO Steve Anderson. NACDS said the DIR fees have in recent years become a catch-all category used increasingly by payers to include various pharmacy price concessions, such as fees related to performance-based programs or fees for participation in a preferred network. Pharmacies are finding themselves in the untenable position of being paid by plan sponsors for prescription services, only to find out later that some of the payment must be returned, according to NACDS.